|
|
|
|
LEADER |
00000nam a22000005i 4500 |
001 |
978-4-431-54412-8 |
003 |
DE-He213 |
005 |
20220119044543.0 |
007 |
cr nn 008mamaa |
008 |
131115s2014 ja | s |||| 0|eng d |
020 |
|
|
|a 9784431544128
|9 978-4-431-54412-8
|
024 |
7 |
|
|a 10.1007/978-4-431-54412-8
|2 doi
|
050 |
|
4 |
|a RC902-918
|
072 |
|
7 |
|a MJR
|2 bicssc
|
072 |
|
7 |
|a MED055000
|2 bisacsh
|
072 |
|
7 |
|a MJR
|2 thema
|
082 |
0 |
4 |
|a 616.61
|2 23
|
245 |
1 |
4 |
|a The Concise Manual of Apheresis Therapy
|h [electronic resource] /
|c edited by Eisei Noiri, Norio Hanafusa.
|
250 |
|
|
|a 1st ed. 2014.
|
264 |
|
1 |
|a Tokyo :
|b Springer Japan :
|b Imprint: Springer,
|c 2014.
|
300 |
|
|
|a XXVII, 418 p. 46 illus., 39 illus. in color.
|b online resource.
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
347 |
|
|
|a text file
|b PDF
|2 rda
|
505 |
0 |
|
|a Part 1. Principles and Technologies -- Chapter 1. Theoretical background of Apheresis Therapy - Norio Hanafusa -- Chapter 2. Methods to Remove Pathogens - Tamami Tanaka -- Chapter 3. Decision to Prescribe PE, DFPP, or PA- Rei Isshiki -- Chapter 4. Plasma Exchange - Daisuke Katagiri -- Chapter 5. Double Filtration Plasmapheresis - Daisuke Katagri -- Chapter 6. Plasma Adsorption- Yasuyuki Watanabe -- Chapter 7. Cryofiltration - Daisuke Katagiri -- Chapter 8. Double Filtration Plasmapheresis Thermo-mode (DF Thermo)- Mizuki Yamano -- Chapter 9. Plasma Diafiltration - Hajime Nakae -- Chapter 10. Direct Plasma Adsorption - Mayumi Miwa -- Chapter 11. Cytapheresis - Yuki Itoh -- Chapter 12. Cell-free and Concentrated Ascites Reinfusion Therapy - Norio Hanafusa -- Part 2. Therapeutic Details -- Chapter 13. Choice of Apheresis Therapy- Eisei Noiri -- Chapter 14. Determination of Dosage and Frequency of Therapy- Norio Hanafusa -- Chapter 15. Vascular Access- Koji Okamoto -- Chapter 16. Anticoagulants - Tetsushi Yamashita -- Part 3. Complications -- Chapter 17. Hypotension - Tsuyoshi Inoue -- Chapter 18. Bleeding Complications and Reduction of Coagulation Factors- Norio Hanafusa -- Chapter 19. Allergies - Motonobu Nakamura -- Chapter 20. Electrolytes Disorders - Motonobu Nakamura -- Chapter 21. Avoiding Complications during Apheresis - Tetsushi Yamashita -- Chapter 22. Infections - Osamu Yamazaki -- Part 4. Autoimmune Disorders -- Chapter 23. Neurological Diseases- Masao Iwagami -- Chapter 24. Dermatological Disorders- Masao Iwagami -- Chapter 25. Kidney Diseases- Masao Iwagami -- Chapter 26. Rheumatoid Arthritis and Collagen Diseases - Hiroko Kanda -- Chapter 27. Blood type incompatible pregnancies - Norio Hanafusa -- Chapter 28. Multiple Myeloma - Tsuyoshi Inoue -- Chapter 29. Dilated Cardiomyopathy - Yoshifumi Hamasaki -- Part 5. Pathogens with Large Molecular Weight.- Chapter 30. Low Density Lipoprotein Apheresis - Kenjiro Honda -- Chapter 31. Endotoxin Adsorption Therapy - Kent Doi -- Part 6. Diseases Necessary to Supply Coagulation Factors -- Chapter 32. Liver Diseases - Kent Doi.- Chapter 33. Thrombotic Thrombocytopenic Purpura and Thrombotic Microangiopathy - Kenjiro Honda.- Chapter 34. Inflammatory Bowel Diseases - Tsuyoshi Inoue.- Chapter 35. Hepatitis C Virus Infection - Shi Lu.- Chapter 36. Drug Intoxications - Motonobu Nakamura -- Chapter 37. Living Related Kidney Transplantation - Hiroo Kawarazaki -- Chapter 38. Peripheral Blood Stem Cell Transplantation- Naoko Watanabe-Okochi -- Part 7. Pediatric Apheresis -- Chapter 39. Apheresis in Children - Motoshi Hattori.
|
520 |
|
|
|a This pocket-sized manual serves as a concise and ideal reference work for therapeutic approaches using apheresis. Covering both basic theory and clinical details to facilitate improved treatment and patient outcomes, the text considers a variety of diseases, including myasthenia gravis, multiple sclerosis, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, nephrotic syndrome, TTP/TMA, dilated cardiomyopathy, and many other conditions. The book also reviews the growing trend toward adopting this unique therapy for a wide range of health management issues such as morbid obesity and/or type 2 diabetes, and for lowering LDL-cholesterol (cholesterol apheresis) in patients unresponsive to medication or lifestyle modification.
|
650 |
|
0 |
|a Nephrology.
|
650 |
|
0 |
|a Internal medicine.
|
650 |
|
0 |
|a Biomedical engineering.
|
650 |
1 |
4 |
|a Nephrology.
|
650 |
2 |
4 |
|a Internal Medicine.
|
650 |
2 |
4 |
|a Biomedical Engineering and Bioengineering.
|
700 |
1 |
|
|a Noiri, Eisei.
|e editor.
|4 edt
|4 http://id.loc.gov/vocabulary/relators/edt
|
700 |
1 |
|
|a Hanafusa, Norio.
|e editor.
|4 edt
|4 http://id.loc.gov/vocabulary/relators/edt
|
710 |
2 |
|
|a SpringerLink (Online service)
|
773 |
0 |
|
|t Springer Nature eBook
|
776 |
0 |
8 |
|i Printed edition:
|z 9784431544111
|
776 |
0 |
8 |
|i Printed edition:
|z 9784431544135
|
856 |
4 |
0 |
|u https://doi.uam.elogim.com/10.1007/978-4-431-54412-8
|z Texto Completo
|
912 |
|
|
|a ZDB-2-SME
|
912 |
|
|
|a ZDB-2-SXM
|
950 |
|
|
|a Medicine (SpringerNature-11650)
|
950 |
|
|
|a Medicine (R0) (SpringerNature-43714)
|